The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways

Blood

Volumn 114, Issue 8, 2009, Pages 1585-1595

  Lim, Megan S ^a   Carlson, Mary L ^b   Crockett, David K ^c   Fillmore, G Chris ^b   Abbott, David R ^b   Elenitoba Johnson, Olaotan F ^c   Tripp, Sheryl R ^c   Rassidakis, George Z ^d   Medeiros, L Jeffrey ^d   Szankasi, Philippe ^c   Elenitoba Johnson, Kojo S J ^a,e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^c ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; MAMMALIAN TARGET OF RAPAMYCIN; NUCLEOPHOSMIN; PROTEIN P42; PROTEIN P44; RAS PROTEIN; P80(NPM ALK) PROTEIN; P80(NPM-ALK) PROTEIN; PROTEIN TYROSINE KINASE; PROTEOME; S6 KINASE;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL ADHESION; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOARCHITECTURE; FUNCTIONAL PROTEOMICS; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING; AMINO ACID SEQUENCE; BIOLOGICAL MODEL; CHEMISTRY; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; LEUKEMIA CELL LINE; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; PROTEOMICS; TISSUE MICROARRAY; TUMOR CELL CULTURE;

AMINO ACID SEQUENCE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JURKAT CELLS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PROTEIN-TYROSINE KINASES; PROTEOME; PROTEOMICS; RIBOSOMAL PROTEIN S6 KINASES; TISSUE ARRAY ANALYSIS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 70349569567     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-204735     Document Type: Article

References (39)

1. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278(5340):1059-1064. (Pubitemid 27517875)
2. Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes. Nat Rev Cancer. 2004;4(3):177-183.
3. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004;4(5):361-370. (Pubitemid 38579482)
4. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, International Agency for Research on Cancer; 2001.
5. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma [published erratum appears in Science. 1995;;267(5196):316-317]. Science. 1994;263(5196):1281-1284.
6. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene. 1994;9(6):1567-1574. (Pubitemid 24163381)
7. Morris SW, Naeve C, Mathew P, et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene. 1997;14(23):2175-2188. (Pubitemid 27248229)
8. Shiota M, Mori S. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Leukemia. 1997;11(suppl 3):538-540. (Pubitemid 27313594)
9. Nieborowska-Skorska M, Slupianek A, Xue L, et al. Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res. 2001;61(17):6517-6523. (Pubitemid 32783259)
10. Zamo A, Chiarle R, Piva R, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene. 2002;21(7):1038-1047. (Pubitemid 34174516)
11. Ruchatz H, Coluccia AM, Stano P, Marchesi E, Gambacorti-Passerini C. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells. Exp Hematol. 2003;31(4):309-315. (Pubitemid 36407607)
12. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol. 1999;17(10):994-999. (Pubitemid 29474856)
13. Hansen KC, Schmitt-Ulms G, Chalkley RJ, Hirsch J, Baldwin MA, Burlingame AL. Mass spectrometric analysis of protein mixtures at low levels using cleavable 13C-isotope-coded affinity tag and multidimensional chromatography. Mol Cell Proteomics. 2003;2(5):299-314.
14. Crockett DK, Lin Z, Elenitoba-Johnson KS, Lim MS. Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene. 2004;23(15):2617-2629. (Pubitemid 38586315)
15. Schumacher JA, Jenson SD, Elenitoba-Johnson KS, Lim MS. Utility of linearly amplified RNA for RT-PCR detection of chromosomal translocations: validation using the t(2;5)(p23;q35) NPMALK chromosomal translocation. J Mol Diagn. 2004;6(1):16-21.
16. Lin Z, Crockett DK, Jenson SD, Lim MS, Elenitoba-Johnson KS. Quantitative proteomic and transcriptional analysis of the response to the p38 mitogen-activated protein kinase inhibitor SB203580 in transformed follicular lymphoma cells. Mol Cell Proteomics. 2004;3(8):820-833. (Pubitemid 39199582)
17. Han DK, Eng J, Zhou H, Aebersold R. Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry. Nat Biotechnol. 2001;19(10):946-951. (Pubitemid 32947573)
18. Bradshaw RA. Revised draft guidelines for proteomic data publication. Mol Cell Proteomics. 2005;4(9):1223-1225. (Pubitemid 41448710)
19. Lim MS, Adamson A, Lin Z, et al. Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index. Blood. 2002;100(8):2950-2956.
20. Zeeberg BR, Feng W, Wang G, et al. GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol. 2003;4(4):R28.
21. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology: The Gene Ontology Consortium. Nat Genet. 2000;25(1):25-29.
22. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood. 2000;96(13):4319-4327.
23. Cussac D, Greenland C, Roche S, et al. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood. 2004;103(4):1464-1471. (Pubitemid 38168663)
24. Pulford K, Morris SW, Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol. 2004;199(3):330-358. (Pubitemid 38580430)
25. Gallagher ED, Gutowski S, Sternweis PC, Cobb MH. RhoA binds to the amino terminus of MEKK1 and regulates its kinase activity. J Biol Chem. 2004;279(3):1872-1877. (Pubitemid 38084456)
26. Liebmann C. G protein-coupled receptors and their signaling pathways: classical therapeutical targets susceptible to novel therapeutic concepts. Curr Pharm Des. 2004;10(16):1937-1958. (Pubitemid 38647579)
27. Danen EH, Sonnenberg A. Integrins in regulation of tissue development and function. J Pathol. 2003;200(4):471-480.
28. Dennis PB, Fumagalli S, Thomas G. Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. Curr Opin Genet Dev. 1999;9(1):49-54.
29. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5′ TOP mRNA translation through inhibition of p70s6k. EMBO J. 1997;16(12):3693-3704. (Pubitemid 27250062)
30. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood. 1998;91(6):2076-2084. (Pubitemid 28185511)
31. Ambrogio C, Voena C, Manazza AD, et al. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood. 2005;106(12):3907-3916. (Pubitemid 41739031)
32. Piva R, Chiarle R, Manazza A, et al. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large cell lymphomas. Blood. 2006;107(2):689-697.
33. Ventura RA, Martin-Subero JI, Knippschild U, et al. Centrosome abnormalities in ALK-positive anaplastic large-cell lymphoma. Leukemia. 2004;18(11):1910-1911. (Pubitemid 39530026)
34. Myers SM, Mulligan LM. The RET receptor is linked to stress response pathways. Cancer Res. 2004;64(13):4453-4463. (Pubitemid 38856916)
35. Janssens V, Goris J, Van Hoof C. PP2A: the expected tumor suppressor. Curr Opin Genet Dev. 2005;15(1):34-41.
36. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 2005;8(5):355-368. (Pubitemid 41579831)
37. Vega F, Medeiros LJ, Leventaki V, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 2006;66(13):6589-6597. (Pubitemid 44085614)
38. Marzec M, Kasprzycka M, Liu X, et al. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene. 2007;26(38):5606-5614. (Pubitemid 47267838)
39. Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene. 2007;26(6):813-821. (Pubitemid 46245735)